{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-020973","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.131107+00:00","generated_at":"2026-05-18T23:27:44.476728+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aytu expands debt facility to $13M term loan plus $1.5M revolver; maturity extended to June 2029 for EXXUA launch","bullets":["Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.","Revolving credit facility expanded by $1.5M incremental advance at SOFR+5.5%, repayable $125K/month starting August 1, 2025.","Provides working capital flexibility as Aytu prepares for commercial launch of EXXUA (gepirone) for MDD expected Q4 2025.","Follows earlier $16.6M public offering closed earlier in June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-020973","json":"https://secwatch.observer/filing/0001437749-25-020973.json","markdown":"https://secwatch.observer/filing/0001437749-25-020973.md","text":"https://secwatch.observer/filing/0001437749-25-020973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/aytu20250611_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:27:44.476728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e45690818becbe392b48db2f2a04ad8feaf4ba5","claim":"AYTU BIOPHARMA, INC amended revolving credit of $1.5 million incremental advance with Eclipse Business Capital LLC at SOFR plus 5.50% maturing June 12, 2029.","evidence_excerpt":"extended the revolving credit facility (the “Eclipse Revolving Loan”) maturity date to June 12, 2029, and increased the potential maximum borrowing base pursuant to a $1.5 million incremental advance (the “Eclipse Incremental Advance”), at an interest rate of the SOFR plus 5.50%","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$1.5 million incremental advance"},{"label":"Counterparty","value":"Eclipse Business Capital LLC"},{"label":"Rate","value":"SOFR plus 5.50%"},{"label":"Maturity","value":"June 12, 2029"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"b1c33db405e55645912b976e07dc65aa69a9b876","claim":"AYTU BIOPHARMA, INC amended term loan of outstanding principal amount of $13.0 million with Eclipse Business Capital LLC maturing June 12, 2029.","evidence_excerpt":"extended the term loan (the “Eclipse Term Loan”) maturity date to June 12, 2029, and increased the Eclipse Term Loan resulting in an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"outstanding principal amount of $13.0 million"},{"label":"Counterparty","value":"Eclipse Business Capital LLC"},{"label":"Maturity","value":"June 12, 2029"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}